Chapter 26: RNA Interference of Genes Related to Alzheimer's Disease Check Access
-
Published:07 May 2010
B. Nawrot, M. Sierant, and A. Paduszynska, in Emerging Drugs and Targets for Alzheimer's Disease: Volume 2: Neuronal Plasticity, Neuronal Protection and Other Miscellaneous Strategies, ed. A. Martinez and A. Martinez, The Royal Society of Chemistry, 2010, vol. 2, ch. 26, pp. 228-268.
Download citation file:
In this chapter, we briefly present the existing hypotheses on the origin and development of Alzheimer's disease (AD) and the pathogenic genes and proteins involved in this neurological disorder. All of these can be considered potential targets for AD therapy. The next section summarises results from the application of RNAi to silence AD-associated genes, including those with mutant alleles, and describes limitations of the RNAi technology related to the delivery of siRNA effectors to the brain and the off-target effects caused by the exogenously delivered siRNAs. Finally, recent improvements in RNAi technology and perspectives for developing siRNA-based drugs for the treatment and prevention of Alzheimer's disease are presented.
